Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc.

In a report released yesterday, William Wood from B. Riley Securities maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $...

Madrigal Pharmaceuticals (MDGL) Receives a Buy from B. Riley Securities

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Madrigal Pharmaceuticals. The company’s shares cl...

Current Quarter	$0.54	Next Quarter	$1.23
Current Year	$-9.66	Next Year	$5.38
QoQ Growth	+127.8%	YoY Growth	+155.7%
3Y EPS CAGR	-14.4%	Target Price	$527.75
Consensus	Buy	Upside	-3.7%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MDGL	$547.96	+1.08%	567.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MDGL	$547.96	+1.1%	567.23K
3
4
5
6

MDGL

MDGL

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Madrigal Pharmaceuticals Inc. Data in Excel

Get Madrigal Pharmaceuticals Inc. Data in Excel